An Open-Label Trial of Tomoxetine in Pediatric Attention Deficit Hyperactivity Disorder
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To collect pilot data assessing the safety, tolerability, and efficacy of tomoxetine, a nonstimulant norepinephrine enhancer, in pediatric attention deficit hyperactivity disorder (ADHD). METHODS: An open-label trial of tomoxetine in pediatric ADHD was conducted as part of a multisite clinical trial. Following a baseline assessment, an ascending dose titration was completed during 10 weekly visits. RESULTS: Ten subjects were enrolled at baseline, with eight completing the study. Seven of the eight remaining subjects met efficacy criteria. Significant decreases in symptom severity ratings by parents and study investigators were found. The medication was well tolerated, with transient appetite suppression the most frequently reported side effect. However, subjects' weights remained stable across study visits. DISCUSSION: These preliminary findings suggest that tomoxetine may hold promise as a treatment for pediatric ADHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Conners, C. K., Sitarenios, G., Parker, J. D. A., & Epstein, J. N. (1998) · Journal of Abnormal Child Psychology · doi:10.1023/a:1022602400621 · Cited by 1,772
Cited by
Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial
ARNOLD, L. E., AMAN, M. G., COOK, A. M., WITWER, A. N., HALL, K. L., THOMPSON, S., & RAMADAN, Y. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000231976.28719.2a · Cited by 260
Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder
Biederman, J., Spencer, T., & Wilens, T. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003973 · Cited by 253
Cheng, J. Y. W., Chen, R. Y. L., Ko, J. S. N., & Ng, E. M. L. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0840-x · Cited by 185
“2003), two studies did not have placebo control groups (Kratochvil et al. 2001; Spencer et al. 2001), two studies compared atomoxetine and methylphenidate osmotic release oral system (OROS) (Kemner et al.”
ResultNon?stimulant medications in the treatment of ADHD
Banaschewski, T., Roessner, V., Dittmann, R. W., Janardhanan Santosh, P., & Rothenberger, A. (2004) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-004-1010-x · Cited by 183
Faraone, S. V., Spencer, T. J., Montano, C. B., & Biederman, J. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.11.1221 · Cited by 144
Metadata
- Authors
- Kratochvil, C. J., Bohac, D., Harrington, M., Baker, N., May, D., & Burke, W. J.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2001-06
- Volume
- 11
- Issue
- 2
- Pages
- 167-170
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W1973772264
- Cited by
- 53
- References
- 1
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Open-Label Trial of Tomoxetine in Pediatric Attention Deficit Hyperactivity Disorder. https://app.cochat.ai/papers/10.1089/104454601750284072
- The paper
- Kratochvil, C. J., Bohac, D., Harrington, M., Baker, N., May, D., & Burke, W. J. (2001). An Open-Label Trial of Tomoxetine in Pediatric Attention Deficit Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/104454601750284072
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.